Company profile: Revenio Group
1.1 - Company Overview
Company description
- Provider of ophthalmological devices and solutions, offering iCare intraocular pressure measurement devices (IC100 handheld; IC200 for multiple patient positions), TONOVET for veterinarians, HOME2 for home IOP monitoring with app data sharing, and fundus imaging systems including EIDON AF (true-color confocal, fully automated) and DRSplus (high-quality images from small pupils and through cataracts/media opacities).
Products and services
- ICare DRSplus: Small-pupil-capable fundus imaging device that captures high-quality retinal images and can image through cataracts and other media opacities
- ICare IC100: Handheld intraocular pressure measurement device used for glaucoma diagnosis and monitoring without the need for anesthetics or calibration
- ICare IC200: Multi-position-capable IOP measurement device that can be used in various patient positions, including sitting, semi-sitting, and lying down
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Revenio Group
Xyall
HQ: The Netherlands
Website
- Description: Provider of molecular pathology solutions: Tissector HT for high-volume molecular diagnostic labs, integrating with digital pathology and LIMS, dissecting over 80 slides per hour with high accuracy; Tissector TT for small to medium labs, integrating with digital pathology and LIMS, dissecting over 30 slides per hour; and an Annotation Suite for remote viewing, annotation, and case confirmation across any digital pathology file format, integrated with molecular pathology workflow.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xyall company profile →
Roche
HQ: Switzerland
Website
- Description: Provider of pharmaceuticals and in-vitro diagnostics, including diagnostic tests and instruments for cancer, diabetes, and infectious diseases; develops medicines for oncology, neurology, virology, inflammation, metabolism, CNS, ophthalmology, immunology, and transplantation; offers digital health solutions for virtual care, decision support, and self-monitoring, plus diabetes management devices and services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Roche company profile →
Vergent Bio
HQ: United States
Website
- Description: Provider of tumor-targeted molecular imaging solutions for cancer surgery, including VGT-309, a fluorescent agent that binds to cathepsins in solid tumors to enable real-time visualization during minimally invasive and robotic-assisted procedures, improving detection and removal of cancerous tissue. Conducts clinical studies evaluating VGT-309’s efficacy and safety in lung cancer surgeries, with potential application in other solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vergent Bio company profile →
DRG International
HQ: United States
Website
- Description: Provider of clinical diagnostic and research ELISAs with distributors, and manufacturer of the DRG:HYBRiD-XL®, a fully automated analyzer for Immunoassays and Clinical Chemistry.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DRG International company profile →
Stratagene
HQ: United States
Website
- Description: Provider of life science research products and services, including instruments, applications, consumables, and expertise. Develops, manufactures, and markets solutions that simplify, accelerate, and improve research for academic, industrial, and government customers in the U.S. and internationally.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stratagene company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Revenio Group
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Revenio Group
2.2 - Growth funds investing in similar companies to Revenio Group
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Revenio Group
4.2 - Public trading comparable groups for Revenio Group
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →